These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Wong SF Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976 [TBL] [Abstract][Full Text] [Related]
7. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition. Venook AP J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248 [TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Jean GW; Shah SR Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402 [TBL] [Abstract][Full Text] [Related]
9. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870 [TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Cohen RB Clin Colorectal Cancer; 2003 Feb; 2(4):246-51. PubMed ID: 12620146 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer. Ready N Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534 [TBL] [Abstract][Full Text] [Related]
12. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711 [TBL] [Abstract][Full Text] [Related]
13. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. Karamouzis MV; Grandis JR; Argiris A JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492 [TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Bunn PA; Franklin W Semin Oncol; 2002 Oct; 29(5 Suppl 14):38-44. PubMed ID: 12422312 [TBL] [Abstract][Full Text] [Related]
15. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Licitra L; Störkel S; Kerr KM; Van Cutsem E; Pirker R; Hirsch FR; Vermorken JB; von Heydebreck A; Esser R; Celik I; Ciardiello F Eur J Cancer; 2013 Apr; 49(6):1161-8. PubMed ID: 23265711 [TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068 [TBL] [Abstract][Full Text] [Related]
17. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. Lenz HJ; Van Cutsem E; Khambata-Ford S; Mayer RJ; Gold P; Stella P; Mirtsching B; Cohn AL; Pippas AW; Azarnia N; Tsuchihashi Z; Mauro DJ; Rowinsky EK J Clin Oncol; 2006 Oct; 24(30):4914-21. PubMed ID: 17050875 [TBL] [Abstract][Full Text] [Related]
18. Development and clinical indications of cetuximab. Labianca R; La Verde N; Garassino MC Int J Biol Markers; 2007; 22(1 Suppl 4):S40-6. PubMed ID: 17520580 [TBL] [Abstract][Full Text] [Related]
19. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Blick SK; Scott LJ Drugs; 2007; 67(17):2585-607. PubMed ID: 18034592 [TBL] [Abstract][Full Text] [Related]